Lexeo Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Lexeo Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $320.00K.
- Lexeo Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $9.00K.
- Lexeo Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $34.00K, a 12.82% decline year-over-year.
- Lexeo Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $39.00K, a 30.00% increase year-over-year.
- Lexeo Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $59.00K, a 87.98% decline from fiscal 2024.
- Lexeo Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $491.00K, a 862.75% increase from fiscal 2023.
- Lexeo Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $51.00K, a 84.64% decline from fiscal 2022.
- Lexeo Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $332.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $320.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $9.00K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $59.00K 10-K · filed 2026-03-30 | |
| 2025-09-30 | $34.00K 10-Q · filed 2025-11-05 | |
| 2024-12-31 | $491.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $39.00K 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $419.00K 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $10.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $51.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $30.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $9.00K 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $12.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $332.00K 10-K · filed 2024-03-11 | |
| 2022-06-30 | $69.00K 10-Q · filed 2023-12-11 | |
| 2022-03-31 | $235.00K 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |